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Abstract. The present study describes an optimized method for 
isolating peripheral blood circulating tumor cells (CTCs) and 
performing KRAS mutation analysis. The approach combines 
isolation of peripheral blood mononuclear cells and immuno-
magnetic labeling with CD45 and CD326 human microbeads 
with KRAS analysis performed with a Therascreen KRAS kit 
by quantitative PCR. KRAS mutations were detected in the 
CTCs of patients with metastatic colorectal cancer (mCRC). 
CTCs may represent an alternative to invasive procedures and 
their analysis may be representative of the current disease 
status of the patient. This proposed analysis may be performed 
in a daily clinical practice.
Introduction
Colorectal cancer (CRC) is one of the most significant world-
wide public health problems (1). During the natural course of 
the disease, ~50% of patients may develop metastasis and up to 
25% of these present with metastatic disease at the moment of 
diagnosis. Advances in the treatment of metastatic colorectal 
cancer (mCRC) include the development of new antitumoral 
agents, including epidermal growth factor receptor-targeted 
monoclonal antibodies (EGFR-mAbs) and tyrosine kinase 
inhibitors, and the use of biomarkers. The KRAS mutational 
status is currently the only biomarker that is predictive of the 
response to therapy using EGFR-mAbs that have been validated 
for clinical practice in mCRC and recommended by the National 
Comprehensive Cancer Network (NCCN) 2012 Guidelines 
(version 1, 2012) (2,3). However, not all mCRC patients with 
wild-type KRAS respond to EGFR-mAb treatment, which 
may be due to alterations in other genes, including BRAF, 
PIK3CA and PTEN (4,5). Furthermore, numerous studies have 
shown discordance in the KRAS mutational status between 
the primary tumor and the metastatic lesions (6-8). Thus, the 
study of KRAS in metastases may have clinical relevance and 
may, at least partly, explain the resistance to EGFR-mAbs in 
patients with KRAS wild-type primary tumors. Metastasis 
involves the concept of circulating tumor cells (CTCs) that are 
associated with the colonization of distant organs. Since the 
study by Ashworth in 1869, in which malignant cells that were 
similar to the primary tumor were identified to circulate in the 
peripheral blood (9), increased efforts, particularly in recent 
years, have focused on the development of reliable methods for 
the enrichment and identification of CTCs (10-12). The present 
study describes an easy, affordable procedure using magnetic 
labeling that allows the isolation of an enriched CTC fraction 
from peripheral blood and, furthermore, the analysis of the 
KRAS mutational status of the CTCs. A comparison between 
the KRAS mutational status in CTCs and the corresponding 
tumor tissue was performed.
Materials and methods
Patients. A total of 23 mCRC patients who were in remission 
or whose primary tumor KRAS mutational status was avail-
able in the patient clinical records were selected for this study. 
Ethylenediaminetetraacetic acid (EDTA)-anticoagulated 
peripheral blood (10 ml) was obtained from each patient, all of 
who exhibited disease progression. This study was approved 
by the ethics committee of the University Clinic of Navarra. 
All the participants provided their informed consent prior to 
blood sample extraction.
Isolation of peripheral blood mononuclear cells (PBMCs; 
time, 1.5 h). When working with anticoagulated peripheral 
blood, PBMCs should be isolated using density gradient 
centrifugation. Ficoll-Paque™ Plus was used for this purpose 
(17-1440-03; GE Healthcare, Buckinghamshire, UK). The 
blood samples were diluted with saline serum (ratio, 1:1) and 
gently added on the top of the Ficoll-Paque Plus medium 
(ratio, 2/3 blood:1/3 Ficoll) taking care not to mix the two 
layers. Following centrifugation for 20 min at 400 x g, the 
PBMCs that were located at the interface layer were collected 
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by inserting the pipette directly through the plasma (alterna-
tively, the upper plasma layer may be removed and the PBMCs 
may be collected). The PBMCs were washed twice with saline 
serum and centrifuged for 8 min at 300 x g. Buffer A was 
added to the PBMCs, which were then centrifuged at 200 x g 
for 10-15 min. Buffer A consisted of phosphate-buffered saline 
(PBS; pH 7.2), 0.5% bovine serum albumin (BSA) and 2 mM 
EDTA). This step was repeated twice. 
Enrichment of circulating tumor cells (time, 2 h). CD45 
Human MicroBeads (130-045-801; Miltenyi Biotec GmbH, 
Bergisch Gladbach, Germany) were used for the enrichment 
of the epithelial tumor cells from the peripheral blood by 
the depletion of the CD45+ cells. The cell number from the 
previous step was measured and following centrifugation at 
300 x g for 10 min and complete aspiration of the superna-
tant, 80 µl buffer A and 20 µl CD45 MicroBeads per 107 total 
cells were added, mixed and refrigerated (4-8˚C) for 15 min. 
Following a wash step with 2 ml buffer A per 107 cells (300 x g 
for 10 min), 500 µl buffer A was added (up to 108 cells). The 
cell suspension was loaded onto a separator column that was 
placed in a magnet (MiniMACS Starting kit; Miltenyi Biotec). 
The magnetically-labeled CD45+ cells were retained within 
the column. The unlabeled cell fraction (CD45- fraction) that 
was enriched in the epithelial tumor cells ran through.
CD326 epithelial cell adhesion molecule (EpCAM) Human 
MicroBeads are used for the enrichment of epithelial tumor 
cells. The cell number from the CD45- fraction that was 
obtained in the previous step was measured and following 
centrifugation at 300 x g for 10 min and complete aspiration of 
the supernatant, 300 µl buffer A and 100 µl FcR reagent (120-
000-442; Miltenyi Biotec) per 5x107 total cells were added 
and mixed. A total of 100 µl CD326 Microbeads were added 
per 5x107 total cells, mixed well and refrigerated at 4-8˚C 
for 30 min. Following a wash step with 5-10 ml buffer A per 
5x107 cells (300 x g for 10 min), 500 µl buffer A was added up 
to 108 cells). The cell suspension was loaded onto a separator 
column placed in a magnet (MiniMACS Starting kit; Miltenyi 
Biotec). Subsequent to the labeling and separating procedures, 
three cell fractions were obtained, CD45+, CD45-/CD326- and 
CD45-/CD326+. A schematic of the procedure is shown in 
Fig. 1. 
DNA purification and quantification (time, 1 h). The 
QIAamp® Mini kit (51101; Qiagen GmbH, Hilden, Germany) 
was used for DNA purification from the cell fractions that 
were obtained previously. The procedure was performed as 
described in the QIAamp Mini kit instructions. DNA quan-
tification was performed using the NaNoDrop-2000/2000c 
Spectrophotometer (Thermo Fisher Scientific Inc., Waltham, 
MA, USA), following the manufacturer's instructions.
KRAS mutational status analysis (time, 2.5 h). All DNA was 
analyzed for a set of seven KRAS point mutations, 12-Ala, Asp, 
Arg, Cys, Ser, Val and 13-Asp, using the Therascreen KRAS 
kit (870011; Qiagen GmbH). The analysis was performed on a 
quantitative PCR instrument (Rotor-Gen Q; Qiagen GmbH). 
Figure 1. Schematic procedure of the KRAS mutational status analysis of peripheral blood isolated CTCs in mCRC patients. PCR, polymerase chain reaction; 
CTCs, circulating tumour cells; mCRC, metastatic colorectal cancer.
Figure 2. Image of the CTC-KRAS mutational status for patient CR6. The 
CD45+ cell fraction (mainly leukocytes) provides a positive signal for the 
control assay corresponding to KRAS exon-4. The CD45-/CD326- cell frac-
tion exhibits a positive signal of the control assay corresponding to KRAS 
exon-4. The CD45-/CD326+ cell fraction exhibits a positive signal of the con-
trol assay corresponding to KRAS exon-4 and a signal for the KRAS-12Ala 
mutation. CTC, circulating tumour cell.
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Results and discussion
Blood samples were studied from 23 mCRC patients whose 
primary tumor KRAS mutational status was available. 
Following the enrichment of the CTCs, three fractions were 
obtained, CD45+, CD45-/CD326- and CD45-/CD326+. The 
KRAS Mutation kit detected seven specific KRAS mutations 
using a region of the KRAS exon-4 as a control. The CD45+ cell 
fraction contained mainly leukocytes, thus, a signal appeared in 
the control assay that corresponds to the KRAS exon-4, but no 
KRAS mutation was detectable, since somatic mutations were 
only present in the fraction that contains the CTCs, if detect-
able. The CD45-/CD326- and CD45-/CD326+ cell fractions 
exhibited a signal of the KRAS exon-4 control due possibly 
to the residual mononuclear cells; however, the amplification 
signal appeared at a higher cycle compared with the corre-
sponding CD45+ since the expected mononuclear cells amount 
was low. The CTCs were identified in the CD45-/CD326+ cell 
fraction and, therefore, the KRAS mutations, if detectable by 
the kit, appear in this fraction. The present study identified a 
correspondence between the primary tumor-KRAS status and 
the CTC-KRAS status in 17 patients (15 wild-type and two 
mutated). In five cases, the tumor-KRAS mutation was not 
detected in the CTCs. In those patients, a low concentration 
of CTCs explained the results as their DNA concentration was 
below the kit detection limits. Notably, another discrepancy was 
identified in one patient (case CR6), who demonstrated a KRAS 
wild-type in the primary tumor and a KRAS-12Ala mutation 
in the CTC enriched cell fraction (Fig. 2). In this case, another 
scenario should be proposed. It is known that in a minority of 
cases (5-10%) the KRAS mutational status is heterogeneous and 
may vary between the primary tumor and the metastasis (13). 
In a recent study, Bossard et al defined a KRAS mutational 
mosaicism, with 4 out of 18 patients showing KRAS status 
discordances between the primary colorectal cancer and the 
metastasis (14). The biological significance of this mosaicism 
is unclear, but indicates diverse metastatic potentials in various 
populations of tumor cells and/or the acquirement of mutations 
during or following metastasis. Bouchahda et al proposed that 
KRAS mutations may be acquired late during the metastatic 
phase of colorectal cancer more frequently than currently 
recognized (15). Furthermore, since CTCs may be consid-
ered as an intermediate step in colonization, their metastatic 
potential depends on a number of genetic abnormalities that 
may include the acquisition of a KRAS mutation. Therefore, the 
CTC-KRAS-Ala mutation that was identified in a patient from 
the present study may lead to an improved adaptation to adverse 
conditions, migration and colonization of distant tissues. By 
the end of the present study, the CR6 patient developed hepatic 
metastasis (tissue from metastases not available) and a change 
from anti-EGFR to Irinotecan-based treatment was considered. 
Future studies examining large series and examining KRAS, 
BRAF, PTEN and PI3K may provide valuable insight into 
the carcinogenesis and metastasizing patterns of mCRC, thus 
guiding treatment options for patients.
In summary, the present study indicated that the isolation 
and analysis of CTCs from the peripheral blood of mCRC 
patients, using a minimally invasive, relatively economical and 
optimized method, may have high clinical relevance. There 
are limitations to the procedure, since during epithelial to 
mesenchymal transition, the expression of epithelial markers 
on CTCs, such as EpCAM may be downregulated and become 
undetectable (16). CTC studies represent an alternative to inva-
sive procedures and their analysis may become a prognostic 
factor, acting as a ‘liquid biopsy’. CTCs are able to survive 
chemotherapy and may indicate a lack of therapeutic efficacy, 
allowing the early end of ineffective treatments and providing 
a representation of the current disease status of the patient.
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